Sangamo's Last Stand: A Delisting, a Promising BLA, and the Race for Cash

The Delisting and the Long Shadow of a Broken Tape

When Sangamo Therapeutics reported its first-quarter results on May 14, the numbers told a story of a company in freefall: a market capitalization of just $66 million, a stock that had shed more than 98% of its value from its 2018 peak, and a recent 90-day price tape showing an 81.7% collapse. The most concrete change, however, was administrative—the company's common stock had been delisted from the Nasdaq Capital Market and began trading on the OTCQB Venture Market under the same ticker, SGMO. CEO Sandy Macrae framed the transition as a matter of survival: “While we are disappointed by the NASDAQ delisting determination, the transition to the OTCQB market will allow Sangamo to maintain access to the public markets while we seek to advance our promising development pipeline.” — Alexander Macrae, Chief Executive Officer · 2026-05-14

The OTCQB Venture Market move is a stark acknowledgement of the company's diminished profile. Yet it also carries a nuance: Sangamo is not a shell—it holds a potentially approvable gene therapy and a pipeline of epigenetic regulators. The tape reflects the market's valuation of the risk of bankruptcy, but the underlying science has not gone away.

A Regulatory Win That Can't Be Funded (Yet)

The most substantive news on the call was regulatory. Sangamo announced that the FDA had reaffirmed that the 104-week eGFR data from all 32 patients in the STAAR study could serve as confirmatory evidence for traditional approval of ST-920, its Fabry disease gene therapy. This builds on the earlier agreement that one-year eGFR slope could support accelerated approval. The rolling BLA submission is underway, with the first two modules submitted. Nathalie Dubois-Stringfellow, Chief Development Officer, noted: “As outlined during our recent fourth quarter earnings call, the rolling submission of a BLA to the U.S. FDA seeking approval of ST-920 under an accelerated approval pathway is in progress with the first 2 modules submitted.” — Nathalie Dubois-Stringfellow, Chief Development Officer · 2026-05-14 She also added that the team is "actively advancing the activity required for the CMC module" with a target to complete the submission as early as this summer, "subject to our ability to secure adequate additional funding." This last qualifier is the crux of the entire story. The regulatory clarity is a positive, but it is not entirely new—the company had previously announced the accelerated approval pathway. In the prior quarter, Macrae had stated: “So we spoke to the agency last October of last year and feel that they reiterated that the eGFR at 1 year could be used to file for accelerated approval.” — Alexander Macrae, Chief Executive Officer · 2026-03-30 What is new is the FDA's explicit statement that no additional confirmatory study is required. On the analyst call, when asked about the impact on BD discussions, CEO Macrae responded: “I hope you can understand that we can't talk about those conversations. I am certain that the people who have been looking at this asset are pleased by the recent affirmation from the agency.” — Alexander Macrae, Chief Executive Officer · 2026-05-14 He emphasized the importance of getting accelerated approval quickly and noted that the 104-week data would be submitted as it becomes available.

The company's own keyword trajectory underscores how the narrative has shifted. BLA submission has been a recurring theme, but in the current quarter the emphasis has moved to neurology pipeline and business development discussions as the company tries to find a partner or capital. The prior quarter's call (March 30, 2026) was dominated by similar concerns: Macrae noted that they had been talking to partners for 18 months, but that "Most of the ones we spoke to last year have now gone. And many of the times, it was because of regulatory uncertainty. We are now speaking to multiple partners and are having good conversations with them." “We have been talking to people for 18 months, a variety of people. Most of the ones we spoke to last year have now gone. And many of the times, it was because of regulatory uncertainty. We are now speaking to multiple partners and are having good conversations with them.” — Alexander Macrae, Chief Executive Officer · 2026-03-30 This is a recurring theme, but the FDA reaffirmation has added a fresh layer of certainty that could finally push a deal across the line.

The Funding Crunch and the Path Forward

The fundamentals paint a grim picture. Total revenue for the latest quarter was just $1 million, down 78% year-over-year, after peaking at $158 million in early 2023 (driven by a Pfizer milestone). Operating income was -$32 million, and the company burned ~$20 million in free cash flow. Liabilities to assets stood at a precarious 131.6%, reflecting a balance sheet that is deeply underwater. The company has explicitly warned about going concern, and the CEO acknowledged on the call that they are "pursuing a number of opportunities to raise additional capital, including evaluating all strategic options to maximize the value of Sangamo's assets."

The adequate additional funding is the single biggest variable. The company has a clear regulatory path, but without cash it cannot complete the CMC work or submit the BLA. The market is pricing in a high probability of failure—or a dilutive rescue. Yet the stock's recent 90-day action shows a 61% rally off the lows before another 67% drop, suggesting a coin-flip sentiment.

In contrast, the company's platform technologies—MINT integrase and the STAC-BBB capsid—offer optionality but are further away. The FDA reaffirmation is a validation of the Fabry program, but the company must now convert that into a partnership. As CEO Macrae said in closing remarks:

This remains an important period for Sangamo as we continue to advance our pipeline while actively pursuing strategic opportunities to strengthen our financial position and maximize the value of our assets.

The juxtaposition is stark: a potentially approvable gene therapy for Fabry disease, a rare but serious condition, sits inside a company that has lost nearly all its market value. The next few months will determine whether Sangamo can secure the funding to submit the BLA and bring ST-920 to market, or whether this becomes another casualty of the biotech downturn. The tape is betting against it, but the science and the regulatory path are the strongest cards the company holds.